Brian Mansel Richards

Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom.

Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom.

Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.